Seminars in Nephrology
Volume 24, Issue 4 , Pages 389-394 , July 2004

L-arginine as a therapeutic tool in kidney disease

  • Saulo Klahr

      Affiliations

    • Departments of Internal Medicine, St. Louis, MO, USA
    • Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO, USA
    • Corresponding Author InformationAddress reprint requests to Saulo Klahr, MD, John E. and Adaline Simon Professor of Medicine, Department of Internal Medicine, Washington University School of Medicine, at Barnes-Jewish Hospital (North Campus), Mailstop 90-31-666, 216 S. Kingshighway Blvd, Suite 4300, S. Louis, MO 63110-1092 USA
    • ,
  • Jeremiah Morrissey

      Affiliations

    • Departments of Internal Medicine, St. Louis, MO, USA
    • Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO, USA

References 

  1. Reyes AA, Karl IE, Klahr S. Role of arginine in health and in renal disease. Am J Physiol. 1994;267:F331–F346
  2. Barri YM, Wilcox CS. Salt intake determines the renal response to L-arginine infusion in normal human subjects. Kidney Int. 1998;53:1299–1304
  3. Baylis C, Harton P, Engels K. Endothelial derived relaxing factor controls renal hemodynamics in the normal rat kidney. J Am Soc Nephrol. 1990;1:875–881
  4. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest. 1992;90:278–281
  5. Klahr S. Nephrology forum (Obstructive nephropathy). Kidney Int. 1998;54:286–300
  6. Iyengar R, Stuehr DJ, Marletta MA. Macrophage synthesis of nitrite, nitrate, and N-nitrosamines (Precursors and role of the respiratory burst). Proc Natl Acad Sci U S A. 1987;84:6369–6373
  7. Reyes AA, Martin D, Settle S, et al.  EDRF role in renal function and blood pressure of normal rats and rats with obstructive uropathy. Kidney Int. 1992;41:403–413
  8. Levillain O, Hus-Citharel A, Morel F, et al.  Localization of arginine synthesis along rat nephron. Am J Physiol. 1990;259:F916–F923
  9. Reyes A, Porras B, Chasalow F, et al.  Administration of L-arginine decreases the infiltration of the kidney by macrophages in obstructive nephropathy and puromycin-induced nephrosis. Kidney Int. 1994;45:1346–1354
  10. Porras-Reyes BH, Schreiner GF, Lefkowith JB, et al.  Essential fatty acids are not required for wound healing. Prostaglandins Leukot Essent Fatty Acids. 1992;45:293–298
  11. Dijkstra CD, Dopp EA, Joling P, et al.  The heterogeneity of mononuclear phagocytes in lymphoid organs (Distinct macrophage subpopulations in rat recognized by monoclonal antibodies ED1, ED2 and ED3). Adv Exp Med Biol. 1985;186:409–419
  12. Hegarty NJ, Young LS, Kirwan CN, et al.  Nitric oxide in unilateral ureteral obstruction (Effect on regional renal blood flow). Kidney Int. 2001;59:1059–1065
  13. Morrissey JJ, Ishidoya S, McCracken R, et al.  Nitric oxide generation ameliorates the tubulointerstitial fibrosis of obstructive nephropathy. J Am Soc Nephrol. 1996;7:2202–2212
  14. Purkerson ML, Hoffsten PE, Klahr S. Pathogenesis of the glomerulopathy associated with renal infarction in rats. Kidney Int. 1976;9:407–417
  15. Reyes AA, Purkerson ML, Karl I, et al.  Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kidney Dis. 1992;20:168–176
  16. Ashab I, Peer G, Blum M, et al.  Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int. 1995;47:1515–1521
  17. Aiello S, Noris M, Todeschini M, et al.  Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney Int. 1997;52:171–181
  18. Reyes AA, Karl IE, Kissane J, et al.  L-arginine administration prevents glomerular hyperfiltration and decreases proteinuria in diabetic rats. J Am Soc Nephrol. 1993;4:1039–1045
  19. Bank N, Aynedjian HS. Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int. 1993;43:1306–1312
  20. Corbett JA, Tilton RG, Chang K, et al.  Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes. 1992;41:552–556
  21. Xia Y, Zweier JL. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc Natl Acad Sci U S A. 1997;94:6954–6958
  22. Klahr S. Can L-arginine manipulation reduce renal disease?. Semin Nephrol. 1999;19:304–309
  23. Saunder A, Danielewicz R, Ametani M, et al.  L-arginine in a 5-day perfusion of canine kidneys. Transplant Proc. 1993;25:3004–3005
  24. Shoskes DA, Xie Y, Gonzalez-Cadavid NF. Nitric oxide synthase activity in renal ischemia-reperfusion injury in the rat (Implications for renal transplantation). Transplantation. 1997;63:495–500
  25. Erkasap S, Ates E. L-arginine-enriched preservation solution decreases ischaemia/reperfusion injury in canine kidneys after long-term cold storage. Nephrol Dial Transplant. 2000;15:1224–1227
  26. Vos IH, Rabelink TJ, Dorland B, et al.  L-arginine supplementation improves function and reduces inflammation in renal allografts. J Am Soc Nephrol. 2001;12:361–367
  27. Peters H, Border WA, Noble NA. From rats to man (A perspective on dietary L-arginine supplementation in human renal disease). Nephrol Dial Transplant. 1999;14:1640–1650
  28. Lortie MJ, Novotny WF, Peterson OW, et al.  Agmatine, a bioactive metabolite of arginine; production, degradation, and functional effects in the kidney of the rat. J Clin Invest. 1996;97:413–420
  29. Zhang XZ, Ghio L, Ardissino G, et al.  Renal and metabolic effects of L-arginine infusion in kidney transplant recipients. Clin Nephrol. 1999;52:37–43
  30. Wu G, Morris SM. Arginine metabolism (Nitric oxide and beyond). Biochem J. 1998;336:1–17
  31. Kasiske BL, Guijarro C, Massy ZA, et al.  Cardiovascular disease after renal transplantation. J Am Soc Nephrol. 1996;7:158–165
  32. Gouvas G, Tentolouris C, Tousoulis D, et al.  Therapeutic modification of the L-arginine-eNOS pathway in cardiovascular diseases. Atherosclerosis. 2001;154:255–267
  33. Kelly KJ, Molitoris BA. Acute renal failure in the new millennium (Time to consider combination therapy). Semin Nephrol. 2000;20:4–19
  34. Schneider R, Raff U, Vonberger N, et al.  L-arginine counteracts nitric oxide-deficiency and improves the recovery phase of ischemic acute renal failure in rats. Kidney Int. 2003;64:216–225
  35. Basile DP, Donohoe DL, Roethe K, et al.  Chronic renal hypoxia after acute ischemic injury (Effects of L-arginine on hypoxia and secondary damage). Am J Physiol. 2003;284:F338–F348
  36. Drexler H, Zeiher AM, Meinzer K, et al.  Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet. 1991;338:1546–1550
  37. Creager MA, Gallagher SJ, Girerd XJ, et al.  L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 1992;90:1248–1253
  38. Egashira K, Hirooka Y, Kuga T, et al.  Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation. 1996;94:130–134
  39. Drexler H, Fischell TA, Pinto FJ, et al.  Effect of L-arginine on coronary endothelial function in cardiac transplant recipients. Circulation. 1994;89:1615–1623

PII: S0270-9295(04)00058-0

doi: 10.1016/j.semnephrol.2004.04.010

Seminars in Nephrology
Volume 24, Issue 4 , Pages 389-394 , July 2004

Article Tools

* Image Usage & Resolution